Recombinant human endostatin combined with paclitaxel-cisplatin chemotherapy in treatment of human breast cancer xenograft in nude mice
- VernacularTitle:重组人内皮抑素联合紫杉醇+顺铂化疗方案治疗人乳腺癌祼鼠移植瘤的研究
- Author:
Li DENG
;
Xuanzhen ZHANG
;
Weidong WANG
;
Zhengtang CHEN
;
Zhenghuai CAO
- Publication Type:Journal Article
- Keywords:
breast cancer;
recombinant human endostatin;
chemotherapy;
nude mice
- From:Journal of Third Military Medical University
2003;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the anti-angiogenesis and tumor inhibitory effects of recombinant human endostatin(rhES)combined with paclitaxel-cisplatin chemotherapy(TP regimen)on xenograft tumors in nude mice of human breast carcinoma cell MCF-7.Methods Forty-eight xenograft nude mice were randomized into group A and group B,then every group were divided 4 subgroups,that is,TP group(cisplatin 20 mg/kg at days 1,7 and 14,and paclitaxel 5 mg/kg at days 1 and 7,i.p.),rhES group(rhES 10 mg?kg-1?d-1 for 14 d,i.v.),rhES+TP group(combined treatment as above-mentioned),and control group(normal saline,i.v.).Inhibitory rate of xenograft and tumor growth curve was calculated and plotted.Serum VEGF level was determined by ELISA,microvessel density(MVD)in tumors was measured by immunohistochemistry,and cell apoptosis was examined by TUNEL staining.Survival time was observed in group B.Results Serum VEGF and MVD was significantly lower in rhES+TP group than in other groups(P
